InsiderTrades.com logo
William Mariner Greenman net worth and biography
  • Phone
  • Email
  • Website

William Greenman Biography and Net Worth

CEO of Cerus
Mr. Greenman was named our President and Chief Executive Officer in April 2011. He had been Cerus’ Chief Business Officer since April 2010. Previously, he was senior vice president, business development and marketing. From 2006 to 2008, he held the position of president, Cerus Europe, and prior to that, he served as vice president, business development. Prior to joining Cerus in 1995 as director of business development, he worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman currently is a member of the Board of Directors of Aduro Biotech. He received his B.A.S. in Economics and Biological Sciences from Stanford University.

What is William Mariner Greenman's net worth?

The estimated net worth of William Mariner Greenman is at least $6.32 million as of March 13th, 2025. Mr. Greenman owns 4,238,672 shares of Cerus stock worth more than $6,315,621 as of March 25th. This net worth approximation does not reflect any other assets that Mr. Greenman may own. Additionally, Mr. Greenman receives an annual salary of $1,040,000.00 as CEO at Cerus. Learn More about William Mariner Greenman's net worth.

How old is William Mariner Greenman?

Mr. Greenman is currently 57 years old. There are 5 older executives and no younger executives at Cerus. Learn More on William Mariner Greenman's age.

What is William Mariner Greenman's salary?

As the CEO of Cerus Co., Mr. Greenman earns $1,040,000.00 per year. Learn More on William Mariner Greenman's salary.

How do I contact William Mariner Greenman?

The corporate mailing address for Mr. Greenman and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at ir@cerus.com. Learn More on William Mariner Greenman's contact information.

Has William Mariner Greenman been buying or selling shares of Cerus?

Over the course of the past ninety days, William Mariner Greenman has sold $230,236.35 of Cerus stock. Most recently, William Mariner Greenman sold 71,086 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $1.45, for a transaction totalling $103,074.70. Following the completion of the sale, the chief executive officer now directly owns 4,238,672 shares of the company's stock, valued at $6,146,074.40. Learn More on William Mariner Greenman's trading history.

Who are Cerus' active insiders?

Cerus' insider roster includes Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.

Are insiders buying or selling shares of Cerus?

In the last year, Cerus insiders bought shares 2 times. They purchased a total of 5,000 shares worth more than $9,675.00. In the last year, insiders at the biotechnology company sold shares 15 times. They sold a total of 511,140 shares worth more than $816,701.40. The most recent insider tranaction occured on March, 13th when COO Vivek K Jayaraman sold 29,985 shares worth more than $43,478.25. Insiders at Cerus own 3.4% of the company. Learn More about insider trades at Cerus.

Information on this page was last updated on 3/13/2025.

William Mariner Greenman Insider Trading History at Cerus

William Mariner Greenman Buying and Selling Activity at Cerus

This chart shows William Mariner Greenman's buying and selling at Cerus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$230ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Cerus Company Overview

Cerus logo
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Read More

Today's Range

Now: $1.49
Low: $1.47
High: $1.57

50 Day Range

MA: $1.71
Low: $1.39
High: $2.15

2 Week Range

Now: $1.49
Low: $1.38
High: $2.54

Volume

1,100,269 shs

Average Volume

1,223,835 shs

Market Capitalization

$276.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56